LeydenLabs-Web-Graphic-060123-v01

February 04, 2023

Modeling Covid vaccination strategies for endemic SARS-CoV-2

A new article from Leyden Labs has been published in the European Journal of Epidemiology, titled "SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies.” Read it here.

For the past 2 years, SARS-CoV-2 has been playing a game of “hide-and-seek” with our immune system. We have been blindsided by its rapid evolution as well as its ability to escape immunity from COVID-19 vaccines and natural infection. Our team used epidemiological models to evaluate the implications of short-lasting immunity for future intervention strategies in a SARS-CoV-2 endemic. Continuous viral evolution calls for careful monitoring of new variants, the incidence of long-COVID, vaccine efficacy over time, and more.

LL-Blue

OUR NEW APPROACH  |  OUR TEAM  |  JOIN OUR MISSION   |  NEWS  |  CAREERS  

Contact

Media inquiries

Stay updated

Leyden Laboratories B.V.

Leiden Laboratory
Emmy Noetherweg 2
2333 BK  Leiden
The Netherlands


Leyden Laboratories Co.

Boston Laboratory
201 Dexter Avenue
Watertown
MA 02472
United States


Leyden Labs S.L.

Granada Office
Avda. del Conocimiento 41.A210
Centro de Empresas
Parque Tecnológico de la Salud
18016 Granada
Spain


© Leyden Labs, 2023  |  Privacy Policy  |  Design by Ape to Zebra

Back to top Arrow